Details
Stereochemistry | RACEMIC |
Molecular Formula | C20H24N2OS |
Molecular Weight | 340.482 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(=O)C1=CC=C2SC3=C(C=CC=C3)N(CC(C)N(C)C)C2=C1
InChI
InChIKey=UVOIBTBFPOZKGP-UHFFFAOYSA-N
InChI=1S/C20H24N2OS/c1-5-18(23)15-10-11-20-17(12-15)22(13-14(2)21(3)4)16-8-6-7-9-19(16)24-20/h6-12,14H,5,13H2,1-4H3
Molecular Formula | C20H24N2OS |
Molecular Weight | 340.482 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Propiomazine is a typical antipsychotic, blocking H1 receptors and is primarily indicated in conditions Insomnia. Propiomazine was also used under brand name largon for the relief of restlessness and apprehension, preoperatively or during surgery. In addition largon was used as an adjunct to analgesics for the relief of restlessness and apprehension during labor. But this drug was discontinued.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL231 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.drugs.com/mmx/largon.html |
Palliative | LARGON Approved UseUnknown Launch Date1960 |
||
Sources: https://www.drugs.com/mmx/largon.html |
Palliative | LARGON Approved UseUnknown Launch Date1960 |
||
Primary | Unknown Approved UseUnknown |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.7 h |
20 mg single, intravenous dose: 20 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PROPIOMAZINE serum | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
10.8 h |
single, intramuscular |
PROPIOMAZINE serum | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
8.6 h |
single, oral |
PROPIOMAZINE serum | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
19% |
PROPIOMAZINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Sample Use Guides
Usual adult dose: Preoperative: intramuscular or intravenous: 20 to 40 mg administered in conjunction with 50 mg of meperidine. Sedation during surgery with local, nerve block, or spinal anesthesia: intramuscular or intravenous 10 to 20 mg. Analgesia adjunct, during labor: intramuscular or intravenous, 20 to 40 mg in the early stages of labor, then 20 to 40 mg of propiomazine administered in conjunction with 25 to 75 mg of meperidine when labor is definitely established. Doses may be repeated every three hours, if necessary.
Usual pediatric dose: sedation prior to surgery: preanesthetic or postoperative: children up to 27 kg: Intramuscular or intravenous, 550 mcg (0.55 mg) to 1.1 mg per kg of body; children 2 to 4 years of age: Intramuscular or intravenous, 10 mg; children 4 to 6 years of age: Intramuscular or intravenous, 15 mg; children 6 to 12 years of age: Intramuscular or intravenous, 25 mg.
insomnia: 25 to 50 mg oral
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:21:19 GMT 2023
by
admin
on
Fri Dec 15 16:21:19 GMT 2023
|
Record UNII |
242Z0PM79Y
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29710
Created by
admin on Fri Dec 15 16:21:19 GMT 2023 , Edited by admin on Fri Dec 15 16:21:19 GMT 2023
|
||
|
WHO-ATC |
N05CM06
Created by
admin on Fri Dec 15 16:21:19 GMT 2023 , Edited by admin on Fri Dec 15 16:21:19 GMT 2023
|
||
|
WHO-VATC |
QN05CM06
Created by
admin on Fri Dec 15 16:21:19 GMT 2023 , Edited by admin on Fri Dec 15 16:21:19 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL1201210
Created by
admin on Fri Dec 15 16:21:19 GMT 2023 , Edited by admin on Fri Dec 15 16:21:19 GMT 2023
|
PRIMARY | |||
|
242Z0PM79Y
Created by
admin on Fri Dec 15 16:21:19 GMT 2023 , Edited by admin on Fri Dec 15 16:21:19 GMT 2023
|
PRIMARY | |||
|
DB00777
Created by
admin on Fri Dec 15 16:21:19 GMT 2023 , Edited by admin on Fri Dec 15 16:21:19 GMT 2023
|
PRIMARY | |||
|
8770
Created by
admin on Fri Dec 15 16:21:19 GMT 2023 , Edited by admin on Fri Dec 15 16:21:19 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB10110MIG
Created by
admin on Fri Dec 15 16:21:19 GMT 2023 , Edited by admin on Fri Dec 15 16:21:19 GMT 2023
|
PRIMARY | |||
|
8491
Created by
admin on Fri Dec 15 16:21:19 GMT 2023 , Edited by admin on Fri Dec 15 16:21:19 GMT 2023
|
PRIMARY | |||
|
88245-06-1
Created by
admin on Fri Dec 15 16:21:19 GMT 2023 , Edited by admin on Fri Dec 15 16:21:19 GMT 2023
|
SUPERSEDED | |||
|
DTXSID1023520
Created by
admin on Fri Dec 15 16:21:19 GMT 2023 , Edited by admin on Fri Dec 15 16:21:19 GMT 2023
|
PRIMARY | |||
|
206-646-1
Created by
admin on Fri Dec 15 16:21:19 GMT 2023 , Edited by admin on Fri Dec 15 16:21:19 GMT 2023
|
PRIMARY | |||
|
2298
Created by
admin on Fri Dec 15 16:21:19 GMT 2023 , Edited by admin on Fri Dec 15 16:21:19 GMT 2023
|
PRIMARY | |||
|
3275
Created by
admin on Fri Dec 15 16:21:19 GMT 2023 , Edited by admin on Fri Dec 15 16:21:19 GMT 2023
|
PRIMARY | |||
|
C66486
Created by
admin on Fri Dec 15 16:21:19 GMT 2023 , Edited by admin on Fri Dec 15 16:21:19 GMT 2023
|
PRIMARY | |||
|
735
Created by
admin on Fri Dec 15 16:21:19 GMT 2023 , Edited by admin on Fri Dec 15 16:21:19 GMT 2023
|
PRIMARY | |||
|
4940
Created by
admin on Fri Dec 15 16:21:19 GMT 2023 , Edited by admin on Fri Dec 15 16:21:19 GMT 2023
|
PRIMARY | |||
|
C084591
Created by
admin on Fri Dec 15 16:21:19 GMT 2023 , Edited by admin on Fri Dec 15 16:21:19 GMT 2023
|
PRIMARY | |||
|
100000081378
Created by
admin on Fri Dec 15 16:21:19 GMT 2023 , Edited by admin on Fri Dec 15 16:21:19 GMT 2023
|
PRIMARY | |||
|
m9206
Created by
admin on Fri Dec 15 16:21:19 GMT 2023 , Edited by admin on Fri Dec 15 16:21:19 GMT 2023
|
PRIMARY | Merck Index | ||
|
PROPIOMAZINE
Created by
admin on Fri Dec 15 16:21:19 GMT 2023 , Edited by admin on Fri Dec 15 16:21:19 GMT 2023
|
PRIMARY | |||
|
7284
Created by
admin on Fri Dec 15 16:21:19 GMT 2023 , Edited by admin on Fri Dec 15 16:21:19 GMT 2023
|
PRIMARY | |||
|
362-29-8
Created by
admin on Fri Dec 15 16:21:19 GMT 2023 , Edited by admin on Fri Dec 15 16:21:19 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |